Iannaccone ST - Search Results

1

Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy.

Mercuri E, Darras BT, Chiriboga CA, Day JW, Campbell C, Connolly AM, Iannaccone ST, Kirschner J, Kuntz NL, Saito K, Shieh PB, Tulinius M, Mazzone ES, Montes J, Bishop KM, Yang Q, Foster R, Gheuens S, Bennett CF, Farwell W, Schneider E, De Vivo DC, Finkel RS; CHERISH Study Group. Mercuri E, et al. Among authors: iannaccone st. N Engl J Med. 2018 Feb 15;378(7):625-635. doi: 10.1056/NEJMoa1710504. N Engl J Med. 2018. PMID: 29443664 Free article. Clinical Trial.

2

The gross motor function measure is a valid and sensitive outcome measure for spinal muscular atrophy.

Nelson L, Owens H, Hynan LS, Iannaccone ST; AmSMART Group. Nelson L, et al. Among authors: iannaccone st. Neuromuscul Disord. 2006 Jun;16(6):374-80. doi: 10.1016/j.nmd.2006.03.005. Epub 2006 May 2. Neuromuscul Disord. 2006. PMID: 16632361

3

Modern management of spinal muscular atrophy.

Iannaccone ST. Iannaccone ST. J Child Neurol. 2007 Aug;22(8):974-8. doi: 10.1177/0883073807305670. J Child Neurol. 2007. PMID: 17761652 Review.

4

The test of infant motor performance: reliability in spinal muscular atrophy type I.

Finkel RS, Hynan LS, Glanzman AM, Owens H, Nelson L, Cone SR, Campbell SK, Iannaccone ST; AmSMART Group. Finkel RS, et al. Among authors: iannaccone st. Pediatr Phys Ther. 2008 Fall;20(3):242-6. doi: 10.1097/PEP.0b013e318181ae96. Pediatr Phys Ther. 2008. PMID: 18703961

5

The PedsQL in pediatric patients with Spinal Muscular Atrophy: feasibility, reliability, and validity of the Pediatric Quality of Life Inventory Generic Core Scales and Neuromuscular Module.

Iannaccone ST, Hynan LS, Morton A, Buchanan R, Limbers CA, Varni JW; AmSMART Group. Iannaccone ST, et al. Neuromuscul Disord. 2009 Dec;19(12):805-12. doi: 10.1016/j.nmd.2009.09.009. Epub 2009 Oct 28. Neuromuscul Disord. 2009. PMID: 19846309 Free PMC article.

6

Reliability of telephone administration of the PedsQL Generic Quality of Life Inventory and Neuromuscular Module in spinal muscular atrophy (SMA).

Dunaway S, Montes J, Montgomery M, Battista V, Koo B, Marra J, De Vivo DC, Hynan LS, Iannaccone ST, Kaufmann P. Dunaway S, et al. Among authors: iannaccone st. Neuromuscul Disord. 2010 Mar;20(3):162-5. doi: 10.1016/j.nmd.2009.12.002. Epub 2010 Jan 13. Neuromuscul Disord. 2010. PMID: 20074950

7

Liquid formulation of pentoxifylline is a poorly tolerated treatment for duchenne dystrophy.

Zimmerman A, Clemens PR, Tesi-Rocha C, Connolly A, Iannaccone ST, Kuntz N, Arrieta A, Hache L, Henricson E, Hu F, Mayhew J, Escolar DM. Zimmerman A, et al. Among authors: iannaccone st. Muscle Nerve. 2011 Aug;44(2):170-3. doi: 10.1002/mus.22127. Epub 2011 Jun 14. Muscle Nerve. 2011. PMID: 21674534 Free PMC article. Clinical Trial.

8

Drug treatment for spinal muscular atrophy type I.

Wadman RI, Bosboom WM, van den Berg LH, Wokke JH, Iannaccone ST, Vrancken AF. Wadman RI, et al. Among authors: iannaccone st. Cochrane Database Syst Rev. 2011 Dec 7;(12):CD006281. doi: 10.1002/14651858.CD006281.pub3. Cochrane Database Syst Rev. 2011. PMID: 22161399 Updated. Review.

9

Drug treatment for spinal muscular atrophy type I.

Wadman RI, Bosboom WM, van der Pol WL, van den Berg LH, Wokke JH, Iannaccone ST, Vrancken AF. Wadman RI, et al. Among authors: iannaccone st. Cochrane Database Syst Rev. 2012 Apr 18;(4):CD006281. doi: 10.1002/14651858.CD006281.pub4. Cochrane Database Syst Rev. 2012. PMID: 22513939 Updated. Review.

10

Childhood spinal muscular atrophy: controversies and challenges.

Mercuri E, Bertini E, Iannaccone ST. Mercuri E, et al. Among authors: iannaccone st. Lancet Neurol. 2012 May;11(5):443-52. doi: 10.1016/S1474-4422(12)70061-3. Lancet Neurol. 2012. PMID: 22516079 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

166 results

Search Page